Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity-Reference-Cited by-同舟云学术

Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity

Published:2017-06-07 Issue:7 Volume:12 Page:1883-1892
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Wright Gabriela¹,Golubeva Volha²,Remsing Rix Lily L.¹,Berndt Norbert¹,Luo Yunting³,Ward Grace A.¹⁴,Gray Jhanelle E.⁵,Schonbrunn Ernst¹³,Lawrence Harshani R.¹³,Monteiro Alvaro N.A.²,Rix Uwe¹^ORCID

Affiliation:

1. Drug Discovery Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

2. Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

3. Chemical Biology Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

4. Cancer Biology PhD Program, University of South Florida, Tampa, Florida 33620, United States

5. Thoracic Oncology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

Funder

National Cancer Institute

H. Lee Moffitt Cancer Center and Research Institute

Moffitt Cancer Center

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acschembio.7b00147

Reference44 articles.

1. mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2

2. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase

3. Wee1 kinase as a target for cancer therapy

4. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

5. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives;Journal of Medicinal Chemistry;2024-07-02

2. Wee1 inhibition decouples Cdk1 and Plk1 activities: a role for gradual Cdk1 activation throughout G2 phase;2024-03-17

3. Small molecule agents for triple negative breast cancer: Current status and future prospects;Translational Oncology;2024-03

4. Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors;Critical Reviews in Oncology/Hematology;2024-01

5. Synthesis and biological evaluation of (2‐aminosulfonylpyridin‐6‐yl)pyrazolopyrimidinone derivatives as Wee1 inhibitors for cancer treatment;Bulletin of the Korean Chemical Society;2023-12-06